September 29, 2016 11:28 AM ET

Pharmaceuticals

Company Overview of InSite Vision Incorporated

Company Overview

InSite Vision Incorporated, an ophthalmic product development company, engages in developing ophthalmic pharmaceutical products to address unmet eye care needs in the United States. The company develops its products based on its proprietary DuraSite drug delivery technology. It offers AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. The products under development include BromSite, which has completed Phase III clinical trials for the treatment of post-operative inflammation, as well as the prevention of post-operative eye pain; DexaSite, which has completed Phase III clini...

965 Atlantic Avenue

Alameda, CA 94501

United States

Founded in 1986

29 Employees

Phone:

510-865-8800

Fax:

510-865-5700

Key Executives for InSite Vision Incorporated

Chief Executive Officer
Age: 51
Chief Financial Officer and Vice President
Age: 72
Vice President of Operations and Quality
Age: 61
Chief Medical Officer, Vice President of Clinical & Regulatory Affairs and Member of Scientific Advisory Board
Age: 51
Vice President of Development and Secretary
Age: 67
Compensation as of Fiscal Year 2016.

InSite Vision Incorporated Key Developments

InSite Vision Incorporated’s Common Stock Deleted From Other OTC

InSite Vision Incorporated’s common stock has been deleted from Other OTC, effective November 3, 2015. The deletion was due to acquisition/merger/amalgamation.

InSite Vision Incorporated Announces Management Changes

InSite Vision Incorporated announced that, with the terms of the merger agreement and effective as of the effective time, Timothy McInerney, Brian Levy, Robert O'Holla, Timothy Ruane, Craig Tooman, Anthony J. Yost, who together comprised the entire Board of Directors of the company prior to the effective time, resigned as members of the Board of Directors of the company. Immediately following the effective time, Kal Sundaram, Sunil Mehta and Javesh Shah, the directors of merger sub immediately prior to the effective time, became the directors of the company.

InSite Vision Incorporated, Board Meeting, Sep 04, 2015

InSite Vision Incorporated, Board Meeting, Sep 04, 2015.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact InSite Vision Incorporated, please visit www.insitevision.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.